Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.
View all episodes
By BiotechTV
4.3
66 ratings
Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.
3,223 Listeners
1,902 Listeners
123 Listeners
324 Listeners
61 Listeners
9,960 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
514 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
46 Listeners